930

Abstract

blood components units within two 6-hour periods, before and after CFCs administration (Table 1). Results: Eighty-three patients (median 58 years [IQR 45, 65] years, 59 % male, SOFA 7 [4,10]) were included. Thirty-six (43.4 %) underwent cardiac surgery, 31 (37.3 %) liver transplantation and 16 (19.3 %) other surgeries. Fifty-seven (68.7%) received Riastap® (2 g. [2, 4]), nine (10.8%) Prothromplex® (1,200 U. [600, 1800] and 17 (20.5%) both CFCs. Crude mortality was 50.6% (42 patients) with 62 % out of all deaths being considered as due to bleeding. Table 1. Laboratory values and blood transfusion within 6 hour before [1] and 6 hour after [2] of CFCs administration INR [1]=2.0 (1.2 -2.8); [2]=1.6 (1.3 -2.2) Fibrinogen (g/L) [1]=1.1 (0.8 -2.3);[2]=1.8 (1.2 -2.4) Hemoglobin (g/L) [1]= 83 (65, 99);[2]= 89 (75, 100) Platelets (x 109) [1]=85 (44, 164);[2]=81 (58, 113) RBC (units) [1]= 4 (3, 7);[2]=2 ( 1, 4); overall= 9 (6, 15) FFP (units) [1]= 2 (0, 3); [2]= 0 (0, 2); overall= 3 (1, 5) Platelets (pool) [1]= 1 (0, 2);[2]= 0 (0, 1); overall= 2 (1, 3) Bleeding (mL) [1]= 1200 (700, 2000);[2]= 500 (240, 1250); overall=1900 (500, 2700) All differences (6h. before vs. after, were significative); RBC: red blood cells; FFP: fresh frozen plasma Conclusions: In bleeding, over transfused patients with coagulopathy, CFCs administrations were associated with a decrease of transfusion requirements, although mortality rates were unacceptably high. Further investigation to ascertain whether an earlier, specific and sufficient (ROTEM-guided) administration of CFCs might improve patient outcome is warranted